Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karan Motiani

Hospitalist Florence, KY Medical Doctor

NPI 1003251026 CMS profile 1384402

4900 Houston Rd, 231 Albert Sabin Way Ml, Florence, KY 41042

Open in the dashboard

General payments

$1,086

17 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karan Motiani of Florence, KY is reported in the CMS Open Payments database as having received $1,086 across 17 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $287 3
2019 General $799 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karan Motiani
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Karan Motiani were reported at $287. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Karan Motiani Hospitalist median Middle half National median
2019 $799 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $0 $70 $23–$167 $132
2022 $0 $85 $27–$174 $149
2023 $0 $89 $30–$191 $160
2024 $0 $95 $29–$204 $164
2025 $287 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $344 7 payments
  2. Amgen Inc. $270 3 payments
  3. Pfizer Inc. $121 1 payment
  4. Novartis Pharmaceuticals Corporation $112 1 payment
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $105 1 payment
  6. AstraZeneca Pharmaceuticals LP $78 1 payment
  7. Shockwave Medical, Inc $22 1 payment
  8. Mylan Specialty L.P. $18 1 payment
  9. Portola Pharmaceuticals, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,035 12 payments
  2. Travel and Lodging $51 5 payments
Products named General payments · program years 2019–2025
  1. SAPIEN 3 Ultra RESILIA $209 2 payments
  2. Repatha $148 2 payments
  3. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $135 5 payments
  4. AIMOVIG $122 1 payment
  5. ELIQUIS $121 1 payment
  6. ENTRESTO $112 1 payment
  7. JARDIANCE $105 1 payment
  8. Vascular Lithotripsy $22 1 payment
  9. YUPELRI $18 1 payment
  10. ANDEXXA $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

218

Median for Hospitalist: 109

Drug cost

$8,831

Median for Hospitalist: $6,399

Branded share of claims

27.1%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $7,077
Naloxone Hcl Generic 12 $799
Cefdinir Generic 37 $319
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 18 $128
Prednisone Generic 31 $122
Pantoprazole Sodium Generic 18 $111
Levofloxacin Generic 17 $100
Doxycycline Hyclate Generic 17 $48
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $44
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 13 $38

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$84,688

Medicare's payments for the services billed

Medicare patients

263

Average age 76

Services billed

986

147 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Chronic kidney disease 62%
Ischemic heart disease 55%
Depression 53%
Diabetes 49%
Heart failure 48%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

17 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record